A new study finds just 6% of clinical trials used to approve new drugs in the U.S. reflect the country’s racial and ethnic makeup, with an increasing trend of trials underrepresenting Black and Hispanic individuals.
FDA drug trials exclude a widening slice of Americans, research reveals
